Exosome-Derived Dystrophin from Allograft Myogenic Progenitors Improves Cardiac Function in Duchenne Muscular
1Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 160, Pujian Road, Shanghai, 200127, China.
Abstract:
Progressive cardiomyocyte loss in Duchenne muscular dystrophy (DMD) leads to cardiac fibrosis, cardiomyopathy, and eventually heart failure. In the present study, we observed that myogenic progenitor cells (MPC) carry mRNA for the dystrophin gene. We tested whether cardiac function can be improved in DMD by allograft transplantation of MPC-derived exosomes (MPC-Exo) into the heart to restore dystrophin protein expression. Exo from C2C12 cells (an MPC cell line) or vehicle were delivered locally into the hearts of MDX mice. After 2 days of treatment, we observed that MPC-Exo restored dystrophin expression in the hearts of MDX mice, which correlated with improved myocardial function in dystrophin-deficient MDX mouse hearts. In conclusion, this study demonstrated that allogeneic WT-MPC-Exo transplantation transiently restored dystrophin gene expression and improved cardiac function in MDX mice, suggesting that allogenic exosomal delivery may serve as an alternative treatment for cardiomyopathy of DMD.
Insights
Exosomes derived from myogenic progenitor cells (MPC-Exo) can restore dystrophin expression and improve heart function in Duchenne muscular dystrophy (DMD) models. This suggests exosomal delivery is a potential treatment for DMD cardiomyopathy.
Area of Science:
- Biomedical Engineering
- Regenerative Medicine
- Molecular Biology
Background:
- Duchenne muscular dystrophy (DMD) causes progressive heart muscle loss, leading to heart failure.
- DMD is characterized by a lack of dystrophin protein, essential for muscle integrity.
- Current treatments for DMD cardiomyopathy are limited.
Purpose of the Study:
- To investigate if exosomes derived from myogenic progenitor cells (MPC-Exo) can restore dystrophin expression and improve cardiac function in a mouse model of DMD.
- To evaluate the therapeutic potential of allogeneic exosomal transplantation for DMD-associated cardiomyopathy.
Main Methods:
- Myogenic progenitor cells (MPC) were identified to carry dystrophin gene mRNA.
- Exosomes were isolated from C2C12 cells (an MPC cell line).
- MPC-derived exosomes (MPC-Exo) or vehicle were delivered directly into the hearts of dystrophin-deficient MDX mice.
Main Results:
- MPC-Exo treatment led to the restoration of dystrophin protein expression in the hearts of MDX mice.
- This restoration of dystrophin correlated with improved myocardial function in the treated MDX mice.
- The therapeutic effects were observed within 2 days of exosome delivery.
Conclusions:
- Allogeneic transplantation of wild-type MPC-Exo can transiently restore dystrophin expression in DMD mouse hearts.
- Exosomal delivery of genetic material shows promise as an alternative therapeutic strategy for DMD cardiomyopathy.
- Further research into exosome-based therapies could offer new avenues for treating DMD patients.
More Related Videos
07:44CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
Published on: September 14, 2019
10:03Transplantation of Induced Pluripotent Stem Cell-derived Mesoangioblast-like Myogenic Progenitors in Mouse Models of Muscle Regeneration
Published on: January 20, 2014
Related Concept Videos
The Muscular System
The Derivative as a Function
Derivatives of the Trigonometric Functions
Derivatives of Logarithmic Functions
Second Derivatives of Implicit Functions
Derivatives of Inverse Trigonometric Functions
